Department of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University, Japan.
J Atheroscler Thromb. 2009 Oct;16(5):621-6. doi: 10.5551/jat.497.
Recently, a novel device for measuring the cardio-ankle vascular index (CAVI) as an arterial stiffness parameter has been developed. In this study, we evaluated the effect of angiotensin II receptor blocker (ARB) and calcium channel (Ca) blocker on CAVI in type 2 diabetic patients with hypertension.
Seventy type 2 diabetes mellitus patients with hypertension were enrolled and randomly divided into two groups. One group was administered olmesartan medoxomil 20 mg/day [DOSAGE ERROR CORRECTED] for 12 months (ARB group), and the other group was administered amlodipine besilate 5 mg/day for 12 months (Ca blocker group).
In the ARB group, a significant decrease in CAVI was observed after 12 months; however, no significant change in CAVI was observed in the Ca blocker group although changes in blood pressure were almost the same. By simple regression analyses, CAVI changes correlated positively with 8-OHdG changes.
Olmesartan, an ARB, improved arterial stiffness more than amlodipine, and this effect might be due to not only the blood pressure-lowering effect but also to reducing the potential of oxidative stress recognized in olmesartan.
最近，一种新型的测量心血管踝动脉指数（CAVI）的设备已被开发出来，作为动脉僵硬度的参数。本研究旨在评估血管紧张素Ⅱ受体阻滞剂（ARB）和钙通道（Ca）阻滞剂对 2 型糖尿病伴高血压患者 CAVI 的影响。
共纳入 70 例 2 型糖尿病伴高血压患者，随机分为两组。一组给予奥美沙坦酯 20 mg/天[剂量错误修正]治疗 12 个月（ARB 组），另一组给予苯磺酸氨氯地平 5 mg/天治疗 12 个月（Ca 阻滞剂组）。
ARB 组治疗 12 个月后 CAVI 显著降低，而 Ca 阻滞剂组 CAVI 无显著变化，尽管血压变化几乎相同。简单回归分析显示，CAVI 变化与 8-OHdG 变化呈正相关。
奥美沙坦酯，一种 ARB，改善动脉僵硬度的作用优于氨氯地平，这种作用可能不仅与降压作用有关，还与奥美沙坦酯降低氧化应激的潜在作用有关。
